We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
LGC Clinical Diagnostics

Download Mobile App




Acute COVID-19 Infections Are Characterized by Elevated Blood Levels of IL-26

By LabMedica International staff writers
Posted on 22 Nov 2022
Print article
Image: Mild versus severe immune response during COVID-19 infection (Photo courtesy of Wikimedia Commons)
Image: Mild versus severe immune response during COVID-19 infection (Photo courtesy of Wikimedia Commons)

The most severe form of COVID-19 infection is characterized by elevated levels of the cytokine interleukin-26 (IL-26) in the blood.

IL-26 is an inflammatory mediator and a driver of chronic inflammation that may be categorized as a kinocidin due to its ability to act as a carrier of extracellular DNA and as an antimicrobial molecule through its capacity to form pores in bacterial membranes. IL-26 is released by several immune and structural cells following stimulation of toll-like receptors (TLRs), whereupon it can directly inhibit viral replication and enhance neutrophil chemotaxis. Given these unique properties, IL-26 has emerged as an intriguing mediator of host defense in the lungs. However, the role of IL-26 in COVID-19 has not been thoroughly investigated.

To correct this lapse, investigators at the Karolinska Institutet (Stockholm, Sweden) worked with 49 patients who had been hospitalized with SARS-CoV-2-infection, 44 of whom had severe symptoms and needed oxygen therapy. A control group of 27 healthy individuals was also recruited. The investigators measured levels of IL-26 protein and other inflammatory compounds blood samples obtained from the patients and control subjects.  

Results revealed that IL-26 was markedly increased in blood samples from the acutely ill patients, and that the concentration of IL-26 correlated with those of the neutrophil-mobilizing cytokines IL-8 and TNFalpha, respectively. Moreover, the increase in blood IL-26 correlated with enhanced surface expression of CD47 on blood neutrophils isolated from patients with acute COVID-19. In addition, the results showed that the blood concentration of IL-26 correlated with that of increased lactate dehydrogenase, an established marker of tissue damage, and decreased mean corpuscular hemoglobin (MCH), a previously verified hematological aberration in COVID-19, both of which are associated with severe disease.

Taken together, the findings indicated that increased systemic IL-26 associated with markers of hyperinflammation and tissue damage in patients with acute COVID-19, suggesting that it may be a potential target for diagnosis, monitoring, and therapy in this disease.

“We already know that IL-26 is engaged in mobilizing immune cells that combat bacterial infections in the lungs and also in chronic respiratory disease in humans,” said senior author Dr. Anders Lindén, professor of environmental medicine at the Karolinska Institutet. “What is more, IL-26 has antiviral and antibacterial effects. Our discovery gives us a potential biomarker for severe COVID-19, but given the antiviral effects of IL-26, we may also have identified a new therapeutic target.”

The association between elevated IL-26 and acute COVID-19 was discussed in the November 17, 2022, online edition of the journal Frontiers in Immunology.

Related Links:
Karolinska Institutet

Gold Member
Antipsychotic TDM Assays
Saladax Antipsychotic Assays
Verification Panels for Assay Development & QC
Seroconversion Panels
New
Chagas Disease Test
LIAISON Chagas
New
FOB+Transferrin+Calprotectin+Lactoferrin Test
CerTest FOB+Transferrin+Calprotectin+Lactoferrin Combo Test

Print article

Channels

Clinical Chemistry

view channel
Image: The GlycoLocate platform uses multi-omics and advanced computational biology algorithms to diagnose early-stage cancers (Photo courtesy of AOA Dx)

AI-Powered Blood Test Accurately Detects Ovarian Cancer

Ovarian cancer ranks as the fifth leading cause of cancer-related deaths in women, largely due to late-stage diagnoses. Although over 90% of women exhibit symptoms in Stage I, only 20% are diagnosed in... Read more

Immunology

view channel
Image: The cancer stem cell test can accurately choose more effective treatments (Photo courtesy of University of Cincinnati)

Stem Cell Test Predicts Treatment Outcome for Patients with Platinum-Resistant Ovarian Cancer

Epithelial ovarian cancer frequently responds to chemotherapy initially, but eventually, the tumor develops resistance to the therapy, leading to regrowth. This resistance is partially due to the activation... Read more

Technology

view channel
Image: The new algorithms can help predict which patients have undiagnosed cancer (Photo courtesy of Adobe Stock)

Advanced Predictive Algorithms Identify Patients Having Undiagnosed Cancer

Two newly developed advanced predictive algorithms leverage a person’s health conditions and basic blood test results to accurately predict the likelihood of having an undiagnosed cancer, including ch... Read more

Industry

view channel
Image: The collaboration aims to leverage Oxford Nanopore\'s sequencing platform and Cepheid\'s GeneXpert system to advance the field of sequencing for infectious diseases (Photo courtesy of Cepheid)

Cepheid and Oxford Nanopore Technologies Partner on Advancing Automated Sequencing-Based Solutions

Cepheid (Sunnyvale, CA, USA), a leading molecular diagnostics company, and Oxford Nanopore Technologies (Oxford, UK), the company behind a new generation of sequencing-based molecular analysis technologies,... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.